RobertSMannelMD

Obstetrics & Gynecology • Oklahoma City, OK

Gynecologic Oncology

Professor of Obstetrics & Gynecology, University Okla College of Medicine

Join to view full profile

Are you Dr. Mannel?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 89 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
825 NE 10th St
Oupb5200
Oklahoma City, OK 73104
Phone+1 405-271-7770
Is this information wrong?

Summary

Dr. Robert Mannel, MD is an obstetrician/gynecologist in Oklahoma City, Oklahoma. He is currently licensed to practice medicine in Oklahoma, California, and Texas. He is affiliated with OU Health, SSM Health St. Anthony Hospital - Oklahoma City, and INTEGRIS Baptist Medical Center.

Education & Training

University of California (Irvine)Fellowship, Gynecologic Oncology, 1986 - 1989
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Obstetrics and Gynecology, 1982 - 1986
University of Texas Medical Branch School of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 1986 - Present
OK State Medical License 1989 - 2024
TX State Medical License 1983 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
Oklahoma Magazine Castle Connolly, 2009-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 3
Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 1
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 2
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1, Phase 2
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Start of enrollment: 2008 Mar 10
Completed
Phase 2
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes Start of enrollment: 2007 Apr 02
Completed
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors Start of enrollment: 2007 Oct 09
Completed
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Start of enrollment: 2008 Jan 17
Completed
Phase 1
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 27
Completed
Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells Start of enrollment: 2009 Feb 09
Active, not recruiting
Not Applicable
Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Completed
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19
Active, not recruiting
Not Applicable
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01
Completed
Phase 2
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 05
Completed
Phase 1
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 2
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 2
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07
Completed
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 06
Completed
Phase 2
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2011 Jun 06
Completed
Phase 2
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2011 Oct 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 May 23
Completed
Phase 2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Apr 04
Completed
Phase 2
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2011 Mar 01
Completed
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer Start of enrollment: 2011 Apr 04
Active, not recruiting
Phase 1
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21
Completed
Phase 2
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2011 Aug 15
Active, not recruiting
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Start of enrollment: 2011 Apr 12
Active, not recruiting
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2011 Oct 11
Completed
Phase 1
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Dec 12
Completed
Phase 2
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2012 Jul 09
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer Start of enrollment: 2012 Oct 01
Active, not recruiting
Not Applicable
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14
Terminated
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients.
Ke Zhang, Neman Abdoli, Patrik Gilley, Youkabed Sadri, Xuxin Chen, Theresa C Thai, Lauren Dockery, Kathleen Moore, Robert S Mannel, Yuchen Qiu> ;Computers in Biology and Medicine. 2024 Apr 1
Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy.
Neman Abdoli, Ke Zhang, Patrik Gilley, Xuxin Chen, Youkabed Sadri, Theresa Thai, Lauren Dockery, Kathleen Moore, Robert Mannel, Yuchen Qiu> ;Bioengineering. 2023 Nov 20
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncolo...
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger, Robert S Mannel, Koen DeGeest, Ellen M Hartenbach, Rebecca B...> ;Journal of Clinical Oncology. 2023 Sep 1
83 citations
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa, Robert Mannel, Mark S Shahin, Guilherme H Cantuaria, Eugenia Girda, C...> ;The New England Journal of Medicine. 2023 Jun 8
1 citations
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.
Joseph M Unger, Michael LeBlanc, Suzanne George, Norman Wolmark, Walter J Curran Jr, Peter J O'Dwyer, Mitchell D Schnall, Robert S Mannel, Sumithra J Mandrekar, Robert...> ;Journal of Clinical Oncology. 2023 Apr 10
4 citations
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors i...
Omali Pitiyarachchi, Michael Friedlander, James J Java, John K Chan, Deborah K Armstrong, Maurie Markman, Thomas J Herzog, Bradley J Monk, Floor Backes, Angeles Alvare...> ;Gynecologic Oncology. 2022 Sep 1
114 citations
Recent advances and clinical applications of deep learning in medical image analysis.
Xuxin Chen, Ximin Wang, Ke Zhang, Kar-Ming Fung, Theresa C Thai, Kathleen Moore, Robert S Mannel, Hong Liu, Bin Zheng, Yuchen Qiu> ;Medical Image Analysis. 2022 Jul 1
3 citations
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
C G Jackson, K N Moore, L Cantrell, B K Erickson, L R Duska, D L Richardson, L M Landrum, L L Holman, J L Walker, R S Mannel, K M Moxley, L Queimado, A Cohoon, K Ding,...> ;Gynecologic Oncology. 2022 Jul 1
54 citations
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
Maaike H. M. Oonk, Brian Slomovitz, Peter Baldwin, Helena C. van Doorn, Jacobus van der Velden, Joanne A. de Hullu, Katja N. Gaarenstroom, Brigitte F. M. Slangen, Igna...> ;Journal of Clinical Oncology. 2021 Aug 25
8 citations
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
Lari Wenzel, Kathryn Osann, Chelsea O. McKinney, David Cella, Giulia Fulci, Mary J Scroggins, Heather A. Lankes, Victoria Wang, Kenneth P. Nephew, George L. Maxwell, S...> ;Journal of the National Cancer Institute. 2021 Oct 1
4 citations
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation
Bradley J. Monk, Robert L. Coleman, Thomas J. Herzog, Kathleen N. Moore, David M. O'Malley, Leslie M. Randall, Brian M. Slomovitz, Ramez N. Eskander, Bhavana Pothuri, ...> ;Gynecologic Oncology. 2021 Jul 1
5 citations
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)
Megan Buechel, Danielle Enserro, Robert A. Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, Seyedehnafiseh Mirniaharikandehei, Hong Liu, D...> ;Gynecologic Oncology. 2021 May 1
13 citations
Experimental conditions influence the formation and composition of the corona around gold nanoparticles
Md. Nazir Hossen, Chandra Kumar Elechalawar, Virginie Sjoelund, Kathleen N. Moore, Robert S. Mannel, Resham Bhattacharya, Priyabrata Mukherjee> ;Cancer Nanotechnology. 2021 Jan 1
11 citations
Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients.
Xuxin Chen, Wei Liu, Theresa C. Thai, T. Castellano, Camille C. Gunderson, Kathleen N. Moore, Robert S. Mannel, Hong Liu, Bin Zheng, Yuchen Qiu> ;Computer Methods and Programs in Biomedicine. 2020 Dec 1
116 citations
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
David Miller, Virginia L. Filiaci, Robert S. Mannel, David E. Cohn, Takashi Matsumoto, Krishnansu S. Tewari, Paul DiSilvestro, Michael L. Pearl, Peter A. Argenta, Matt...> ;Journal of Clinical Oncology. 2020 Sep 29
11 citations
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report
Monica M. Bertagnolli, Charles D. Blanke, Walter J. Curran, Douglas S. Hawkins, Robert S. Mannel, Peter J. O'Dwyer, Mitchell D. Schnall, Norman Wolmark> ;Cancer. 2020 Dec 1
4 citations
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group ...
Krishnansu S. Tewari, Michael W. Sill, Robert L. Coleman, Carol Aghajanian, Robert S. Mannel, Paul DiSilvestro, Matthew A. Powell, Leslie M. Randall, John H. Farley, S...> ;Gynecologic Oncology. 2020 Jul 26
21 citations
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, J. Chris Brady, Heather A. Lankes, Herbe...> ;Clinical Cancer Research. 2020 Mar 15
76 citations
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Robert L Coleman, Nick M Spirtos, Danielle Enserro, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Jae-Weon Kim, Sang-Yoon Park, Byoung-Gie Kim, Joo-Hyun Nam, K...> ;The New England Journal of Medicine. 2019 Nov 14
13 citations
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Katherine Fuh, James J. Java, John K. Chan, Daniel S. Kapp, Bradley J. Monk, Robert A. Burger, Robert C. Young, William P. McGuire, Maurie Markman, Jeffrey G. Bell, Ro...> ;Gynecologic Oncology. 2019 Aug 1
238 citations
Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer
Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Q. Huang...> ;Journal of Clinical Oncology. 2019 Jun 19
191 citations
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial ...
Marcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin, Vivian E. von Gruenigen, Helen J. Huang, Catheryn M. Yashar, Robert S. Mannel, Jae Weon Kim, Ritu Salani, Pa...> ;Journal of Clinical Oncology. 2019 Apr 17
19 citations
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritone...
Ursula A. Matulonis, Michael W. Sill, Vicky Makker, David G. Mutch, Jay W. Carlson, Christopher J. Darus, Robert S. Mannel, David Bender, Erin K. Crane, Carol Aghajanian> ;Gynecologic Oncology. 2019 Mar 1
5 citations
Current Activities of the Coalition of Cancer Cooperative Groups.
Monica M. Bertagnolli, Susan M. Blaney, Charles D. Blanke, Walter J. Curran, Janet Dancey, Robert S. Mannel, Peter J. O'Dwyer, Mitchell D. Schnall, Norman Wolmark> ;Journal of the National Cancer Institute. 2019 Jan 1
113 citations
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
Rai, K., Anil Korkut, Sobia Zaidi, Rupa S. Kanchi, Shuyun Rao, Nancy R. Gough, Andre Schultz, Xubin Li, Philip L. Lorenzi, Ashton C. Berger, Gordon Robertson, Lawrence...> ;Cell Systems. 2018 Oct 24
Join now to see all

Press Mentions

OU Medicine’s Stephenson Cancer Center to Conduct Clinical Trials for Cancer Patients Infected by COVID-19May 5th, 2020
$20 Million Gift to Stephenson Cancer Center to Help Discover New Ways to Prevent, Diagnose and Treat CancerNovember 15th, 2019
American Cancer Society Awards New Research and Training GrantsOctober 1st, 2019
Join now to see all

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member

Hospital Affiliations

INTEGRIS Baptist Medical CenterOklahoma City, Oklahoma
OU HealthOklahoma City, Oklahoma
SSM Health St. Anthony Hospital - Oklahoma CityOklahoma City, Oklahoma
OU Medical Center EdmondEdmond, Oklahoma